The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study
Open accessAbstract
BACKGROUND: Clinical trials demonstrated that women treated for breast cancer with anthracycline or trastuzumab are at increased risk for heart failure and/or cardiomyopathy (HF/CM), but the generalizability of these findings is unknown. We estimated real-world adjuvant anthracycline and trastuzumab use and their associations with incident HF/CM. METHODS: We conducted a population-based, retrospective cohort study of 12,500 women diagnosed with incident, invasive breast cancer from January 1, 1999 through December 31, 2007, at eight integrated Cancer Research Network health systems. Using administrative procedure and pharmacy codes, we identified anthracycline, trastuzumab, and other chemotherapy use. We identified incident HF/CM following chemotherapy initiation and assessed risk of HF/CM with time-varying chemotherapy exposures vs no chemotherapy. Multivariable Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) with adjustment for age at diagnosis, stage, Cancer Research Network site, year of diagnosis, radiation therapy, and comorbidities. RESULTS: Among 12 500 women (mean age = 60 years, range = 22-99 years), 29.6% received anthracycline alone, 0.9% received trastuzumab alone, 3.5% received anthracycline plus trastuzumab, 19.5% received other chemotherapy, and 46.5% received no chemotherapy. Anthracycline and trastuzumab recipients were younger, with fewer comorbidities than recipients of other chemotherapy or none. Compared with no chemotherapy, the risk of HF/CM was higher in patients treated with anthracycline alone (adjusted HR = 1.40, 95% CI = 1.11 to 1.76), although the increased risk was similar to other chemotherapy (adjusted HR = 1.49, 95% CI = 1.25 to 1.77); the risk was highly increased in patients treated with trastuzumab alone (adjusted HR = 4.12, 95% CI = 2.30 to 7.42) or anthracycline plus trastuzumab (adjusted HR = 7.19, 95% CI = 5.00 to 10.35). CONCLUSIONS: Anthracycline and trastuzumab were primarily used in younger, healthier women and associated with increased HF/CM risk compared with no chemotherapy. This population-based observational study complements findings from clinical trials on cancer treatment safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Benson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
Smith, L. A., Cornelius, V. R., Plummer, C. J., Levitt, G., Verrill, M., Canney, P., & Jones, A. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-337 · Cited by 753
Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J.-H., Davidson, N. E., Geyer, C. E., Martino, S., Mamounas, E. P., Kaufman, P. A., & Wolmark, N. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.0868 · Cited by 717
Owens, M. A., Horten, B. C., & Da Silva, M. M. (2004) · Clinical Breast Cancer · doi:10.3816/cbc.2004.n.011 · Cited by 657
Pinder, M. C., Duan, Z., Goodwin, J. S., Hortobagyi, G. N., & Giordano, S. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4976 · Cited by 634
Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial
Suter, T. M., Procter, M., van Veldhuisen, D. J., Muscholl, M., Bergh, J., Carlomagno, C., Perren, T., Passalacqua, R., Bighin, C., Klijn, J. G. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1611 · Cited by 566
Perez, E. A., Suman, V. J., Davidson, N. E., Sledge, G. W., Kaufman, P. A., Hudis, C. A., Martino, S., Gralow, J. R., Dakhil, S. R., Ingle, J. N., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5467 · Cited by 538
Go, A. S., Yang, J., Ackerson, L. M., Lepper, K., Robbins, S., Massie, B. M., & Shlipak, M. G. (2006) · Circulation · doi:10.1161/circulationaha.105.577577 · Cited by 515
Guarneri, V., Lenihan, D. J., Valero, V., Durand, J.-B., Broglio, K., Hess, K. R., Michaud, L. B., Gonzalez-Angulo, A. M., Hortobagyi, G. N., & Esteva, F. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.9551 · Cited by 361
Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-Based Study
Doyle, J. J., Neugut, A. I., Jacobson, J. S., Grann, V. R., & Hershman, D. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5841 · Cited by 335
Threats to Applicability of Randomised Trials: Exclusions and Selective Participation
Britton, A., McKee, M., Black, N., McPherson, K., Sanderson, C., & Bain, C. (1999) · Journal of Health Services Research & Policy · doi:10.1177/135581969900400210 · Cited by 299
Statin Therapy and Risks for Death and Hospitalization in Chronic Heart Failure
Go, A. S., Lee, W. Y., Yang, J., Lo, J. C., & Gurwitz, J. H. (2006) · JAMA · doi:10.1001/jama.296.17.2105 · Cited by 291
Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer
Perez, E. A., Suman, V. J., Davidson, N. E., Gralow, J. R., Kaufman, P. A., Visscher, D. W., Chen, B., Ingle, J. N., Dakhil, S. R., Zujewski, J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.7045 · Cited by 255
Procter, M., Suter, T. M., de Azambuja, E., Dafni, U., van Dooren, V., Muehlbauer, S., Climent, M. A., Rechberger, E., Liu, W. T.-W., Toi, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.0463 · Cited by 244
Levine, M. N., Pritchard, K. I., Bramwell, V. H. C., Shepherd, L. E., Tu, D., & Paul, N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.423 · Cited by 220
Jones, A. L., Barlow, M., Barrett-Lee, P. J., Canney, P. A., Gilmour, I. M., Robb, S. D., Plummer, C. J., Wardley, A. M., & Verrill, M. W. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604909 · Cited by 213
Russell, S. D., Blackwell, K. L., Lawrence, J., Pippen, J. E., Roe, M. T., Wood, F., Paton, V., Holmgren, E., & Mahaffey, K. W. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6950 · Cited by 200
Martin, M., Villar, A., Sole-Calvo, A., Gonzalez, R., Massuti, B., Lizon, J., Camps, C., Carrato, A., Casado, A., Candel, M. T., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg260 · Cited by 188
Building a Research Consortium of Large Health Systems: The Cancer Research Network
Wagner, E. H. (2005) · Journal of the National Cancer Institute Monographs · doi:10.1093/jncimonographs/lgi032 · Cited by 179
Self-citationPatterns of Use of Chemotherapy for Breast Cancer in Older Women: Findings From Medicare Claims Data
Du, X., & Goodwin, J. S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1455 · Cited by 172
Building a Virtual Cancer Research Organization
Hornbrook, M. C., Hart, G., Ellis, J. L., Bachman, D. J., Ansell, G., Greene, S. M., Wagner, E. H., Pardee, R., Schmidt, M. M., Geiger, A., et al. (2005) · JNCI Monographs · doi:10.1093/jncimonographs/lgi033 · Cited by 158
Self-citationMackey, J. R., Clemons, M. J., Côté, M. A., Delgado, D., Dent, S. F., Paterson, A., Provencher, L., Sawyer, M. B., & Verma, S. (2008) · Current Oncology · doi:10.3747/co.2008.199 · Cited by 154
Martín, M., Esteva, F. J., Alba, E., Khandheria, B. K., de Isla, L. P., García-Sáenz, J. Á., Márquez, A., Sengupta, P. P., & Zamorano, J. L. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0137 · Cited by 141
Feher, O., Vodvarka, P., Jassem, J., Morack, G., Advani, S. H., Khoo, K. S., Doval, D. C., Ermisch, S., Roychowdhury, D., Miller, M. A., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi181 · Cited by 101
Du, X. L., Xia, R., Liu, C., Cormier, J. N., Xing, Y., Hardy, D. S., Chan, W., & Burau, K. D. (2009) · Cancer · doi:10.1002/cncr.24621 · Cited by 77
Untch, M., Muscholl, M. W., Tjulandin, S., Jonat, W., Meerpohl, H. G., Lichinitser, M., Manikhas, A., Coumbos, A., Kreienberg, R., du Bois, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9709 · Cited by 72
Ackland, S. P., Antón, A., Breitbach, G. P., Colajori, E., Tursi, J. M., Delfino, C., Efremidis, A. P., Ezzat, A. A., Fittipaldo, A., Kolarić, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.943 · Cited by 56
Blumle, A., Meerpohl, J. J., Rucker, G., Antes, G., Schumacher, M., & von Elm, E. (2011) · BMJ · doi:10.1136/bmj.d1828 · Cited by 44
Köninki, K., Tanner, M., Auvinen, A. P., & Isola, J. J. (2009) · Breast Cancer Research · doi:10.1186/bcr2322 · Cited by 28
Delate, T., Bowles, E. J. A., Pardee, R., Wellman, R., Habel, L. A., Yood, M. U., Nekhlyudov, L., Goddard, K. A. B., Davis, R. L., McCarty, C. A., et al. (2012) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-1075 · Cited by 24
Self-citation
Cited by
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,030
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.654 · Cited by 1,795
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2014) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2013-0953-sa · Cited by 1,762
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Metadata
- Authors
- Bowles, E. J. A., Wellman, R., Feigelson, H. S., Onitilo, A. A., Freedman, A. N., Delate, T., Allen, L. A., Nekhlyudov, L., Goddard, K. A. B., Davis, R. L., Habel, L. A., Yood, M. U., Mccarty, C., Magid, D. J., Wagner, E. H., & Pharmacovigilance Study Team
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-08-30
- Volume
- 104
- Issue
- 17
- Pages
- 1293-1305
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2105436256
- Cited by
- 566
- References
- 36
- FWCI
- 22.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.